Skip to main navigation
  • Careers
  • Partnerships & Business Development
  • Contact Us
Link to  Esperion Therapeutics, Inc. Homepage
  • Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Products
  • Science
    • Unmet Need
    • Scientific Resources
    • Scientific Advisory Board
    • Pipeline
    • Grants
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Newsroom

Esperion to Participate in Upcoming Virtual Investor Conference
Oct 27, 2021
PDF Version
ESPERION Announces Agreement to Exchange $15 Million in Principal Amount of its 4.00% Convertible Senior Subordinated Notes due 2025 for Common Stock
Oct 25, 2021
PDF Version
ESPERION Announces Plan for Transformative Long-Term Growth
Oct 18, 2021
PDF Version
Esperion to Report Third Quarter 2021 Financial Results November 2, 2021
Oct 12, 2021
PDF Version
ESPERION to Host Investor Webinar on the Current Landscape and Future Directions in the Treatment of Elevated Cholesterol
Sep 07, 2021
PDF Version
  • First page «
  • Previous page ‹
  • …
  • Page 38
  • Page 39
  • Current page 40
  • Page 41
  • Page 42
  • …
  • Next page ›
  • Last page »

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-887-3903, or by email at corporateteam@esperion.com.


 
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903

 
Corporate Inquiries & Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438

 

Email Alerts

  • OUR COMPANY
  • About Us
  • Leadership Team
  • Board of Directors
  • Ethics and Compliance
  • Corporate Governance & Committee Composition
  • PRODUCTS
  • SCIENCE
  • Unmet Need
  • Scientific Resources
  • Scientific Advisory Board
  • Pipeline
  • Grants
  • CAREERS
  • Partnerships & Business Development
  • INVESTORS & MEDIA
  • Overview
  • Newsroom
  • Events
  • Financial Information
  • Stock Information & Analyst Coverage
  • FAQs
  • Contact Us
Great place to work certified | JUN 2024 - JUN 2025 | USA

All trademarks and trade names are the property of their respective owners.

© 2026 Esperion Therapeutics, Inc. All rights reserved.

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines
  • facebook
  • instagram
  • linkedin
  • twitter
  • rss
Search Investors